Hematology/Oncology Meeting Calendar

With advanced melanoma survival rates at 71% for regional metastases and 32% for distant metastases, the need for novel treatments is urgent due to anti-programmed cell death protein-1 (PD-1) resistance in nearly half of metastatic cases. Oncolytic viruses offer a promising solution, with 1 FDA-approved agent and several others under investigation. This live lunch symposium will explore the mechanisms of anti–PD-1 resistance, the latest data on oncolytic viruses, and their role in treatment. Through expert discussions, case presentations, and Q&A sessions, participants will gain insights to enhance their practice and improve patient outcomes. RSVP now to stay ahead in melanoma therapy.

Patients with advanced melanoma face rapid disease progression and require complex treatments. This educational program delves into the latest in immune checkpoint inhibitors (ICIs), which offer improved survival rates and new hope. Through updates on the latest data and real-world case studies, participants will learn to apply emerging evidence to personalized ICI-based treatment plans for BRAF-mutant and wild-type melanoma. RSVP to stay at the forefront of melanoma treatment advancements.